Clinical Trial Results:
A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease
Summary
|
|
EudraCT number |
2004-000394-60 |
Trial protocol |
SE DK |
Global completion date |
18 Jun 2005
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Jan 2023
|
First version publication date |
18 Jan 2023
|
Other versions |
|
Summary report(s) |
ACR16C007 CSR Synopsis Redacted |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.